Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

121. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis.

Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. BACKGROUND: Fast-food consumption has increased greatly in the USA during the past three decades. However, the effect of fast food on risk of obesity and type 2 diabetes has received little attention. We aimed to investigate the association between reported fast-food habits and changes in bodyweight and insulin resistance over a 15-year period in the USA. METHODS: Participants for the CARDIA (...) study included 3031 young (age 18-30 years in 1985-86) black and white adults who were followed up with repeated dietary assessment. We used multiple linear regression models to investigate the association of frequency of fast-food restaurant visits (fast-food frequency) at baseline and follow-up with 15-year changes in bodyweight and the homoeostasis model (HOMA) for insulin resistance. FINDINGS: Fast-food frequency was lowest for white women (about 1.3 times per week) compared with the other

Lancet2017

122. Endothelial inflammation in insulin resistance.

Endothelial inflammation in insulin resistance. CONTEXT: Type 2 diabetes and attendant cardiovascular morbidity are becoming major health concerns globally. Obesity-related type 2 diabetes is rapidly rising in prevalence, probably largely because of increased longevity and sedentary lifestyles. Insulin resistance and type 2 diabetes are associated with increased coronary heart disease, but the severity of glycaemia during the diabetic phase can only to a minor extent explain the increased risk (...) . Increased levels of the acute-phase inflammatory marker, C-reactive protein (CRP), are related to insulin resistance and the metabolic syndrome, suggesting a role for chronic low-grade inflammation. CRP levels might predict the development of type 2 diabetes. STARTING POINT: Subodh Verma and associates (Circulation 2004; 109: 2058-67) recently showed that CRP attenuates the survival, differentiation, and function of endothelial progenitor cells, partly by CRP reducing expression of endothelial nitric

Lancet2017

123. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation.

Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Rising demand for islet transplantation will lead to severe donor shortage in the near future, especially in countries where cadaveric organ donation is scarce. We undertook a successful transplantation of living-donor islets for unstable diabetes. The recipient was a 27-year-old woman who had had brittle, insulin-dependent diabetes mellitus for 12 years. The donor, who was a healthy 56-year-old woman (...) and mother of the recipient, underwent a distal pancreatectomy. After isolation, 408 114 islet equivalents were transplanted immediately. The transplants functioned immediately and the recipient became insulin-independent 22 days after the operation. The donor had no complications and both women showed healthy glucose tolerance. Transplantation of living-donor islets from the distal pancreas can be sufficient to reverse brittle diabetes.

Lancet2017

124. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease.

"Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Adipose tissue expresses cytokines that inhibit insulin signalling pathways in liver and muscle. Obesity also results in impairment of endothelium-dependent vasodilatation in response to insulin. We propose a vasoregulatory role for local deposits of fat around the origin of arterioles supplying skeletal muscle. Isolated first-order arterioles from rat cremaster muscle are under dual (...) regulation by insulin, which activates both endothelin-1 mediated vasoconstriction and nitric-oxide-mediated vasodilatation. In obese rat arterioles, insulin-stimulated NO synthesis is impaired, resulting in unopposed vasoconstriction. We propose that this vasoconstriction is the consequence of production of the adipocytokine tumour necrosis factor alpha from the cuff of fat seen surrounding the origin of the arteriole in obese rats--a depot to which we ascribe a specialist vasoregulatory role. We

Lancet2017

125. Xultophy (insulin degludec and liraglutide) - type 2 diabetes

Xultophy (insulin degludec and liraglutide) - type 2 diabetes Xultophy® (insulin degludec and liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Xultophy® (insulin degludec and liraglutide) Conclusion Xultophy® (insulin degludec and liraglutide) is a combination product for treatment of type 2 diabetes administered by one daily injection consisting of insulin degludec and the GLP-1 receptor agonist (GLP1-RA) liraglutide. The dose (...) is administered by a pre-filled injection pen with a fixed-ratio combination of insulin degludec and liraglutide, which offers a less flexible dose adjustment. The maximum daily dose is 50 dose steps corresponding to 50 units insulin degludec/1.8 mg liraglutide. In clinical studies, Xultophy has been demonstrated to reduce HbA1c more than both insulin degludec, liraglutide and insulin glargin in combination with existing treatment with different oral antidiabetics. Compared to the above-mentioned insulins

Danish Pharmacotherapy Reviews2017

128. LEVEMIR (insulin detemir), long-acting human insulin analogue

LEVEMIR (insulin detemir), long-acting human insulin analogue Haute Autorité de Santé - LEVEMIR (insuline détémir), analogue de l’insuline humaine d’action lente Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments LEVEMIR (insuline détémir), analogue de l’insuline humaine d’action lente Substance active (DCI) insuline détémir DIABETOLOGIE - Nouvelle (...) indication Nature de la demande Extension d'indication Avis de la CT du 21 septembre 2016 Pas d’avantage clinique démontré par rapport à TRESIBA dans la prise en charge du diabète de type 1 de l’enfant âgé de 1 an à 2 ans LEVEMIR a désormais l’AMM dans le diabète de type 1 chez l’enfant dès l’âge de 1 an. Les données cliniques d’efficacité disponibles chez l’enfant entre 1 et 2 ans, sont limitées à une étude de non infériorité versus insuline dégludec portant sur un effectif de 350 enfants diabétiques de

Haute Autorite de sante2017

129. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.

Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. BACKGROUND: The safety and effectiveness of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has not been shown in a free-living, home-use setting. We aimed to assess whether bihormonal bionic pancreas initialised only with body mass can safely reduce mean glycaemia and hypoglycaemia in adults with type (...) 1 diabetes who were living at home and participating in their normal daily routines without restrictions on diet or physical activity. METHODS: We did a random-order crossover study in volunteers at least 18 years old who had type 1 diabetes and lived within a 30 min drive of four sites in the USA. Participants were randomly assigned (1:1) in blocks of two using sequentially numbered sealed envelopes to glycaemic regulation with a bihormonal bionic pancreas or usual care (conventional or sensor-augmented

Lancet2016

130. Glucagon People/Insulin People

Glucagon People/Insulin People Glucagon People/Insulin People | Clinical Correlations Glucagon People/Insulin People November 23, 2016 By Michael Tanner , MD Glucagon : a 29-amino-acid polypeptide secreted by the alpha cells of the pancreas in response to hypoglycemia or starvation. Insulin : a 51-amino-acid polypeptide secreted by the beta cells of the pancreas in response to nutrient consumption. It’s December 13 th , 1932, Camden, New Jersey. You are playing alto sax and clarinet in the reed (...) , and pumpkin cannolis for dessert. Uncle Jack’s parasympathetic nervous system is totally kicked in; he has just nodded out on the sofa in front of the television. The Detroit Lions are losing to the Green Bay Packers 24-0 in the fourth quarter. Aunt Mary Anne gasps and says, “Oh my God! I forgot to put out the blueberry pies!” They are sitting in the oven, untouched. You and your family are running on insulin. The 1430 base pairs that make up the insulin gene on the short arm of everybody’s chromosome 11

Clinical Correlations2016

131. High Molecular Weight Adiponectin Levels are Neither Influenced by Adiponectin Polymorphisms Nor Associated with Insulin Resistance in Mixed-ancestry Hyperglycemic Subjects from South Africa

High Molecular Weight Adiponectin Levels are Neither Influenced by Adiponectin Polymorphisms Nor Associated with Insulin Resistance in Mixed-ancestry Hyperglycemic Subjects from South Africa 28670194 2018 11 13 1452-8258 35 4 2016 Oct Journal of medical biochemistry J Med Biochem High Molecular Weight Adiponectin Levels are Neither Influenced by Adiponectin Polymorphisms Nor Associated with Insulin Resistance in Mixed-ancestry Hyperglycemic Subjects from South Africa. 416-427 10.1515/jomb-2016

Journal of medical biochemistry2016 Full Text: Link to full Text with Trip Pro

132. Insulin degludec (Tresiba) for the treatment of diabetes mellitus

Insulin degludec (Tresiba) for the treatment of diabetes mellitus %PDF-1.5 %���� 54 0 obj > endobj 75 0 obj >/Filter/FlateDecode/ID[ ]/Index[54 44]/Info 53 0 R/Length 97/Prev 204123/Root 55 0 R/Size 98/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$���: �~H�L̚ � D(�q $[ b�\� mJ "Hp~��$@\�� w�}&F�� ��&�3�`�uS endstream endobj startxref 0 %%EOF 97 0 obj >stream h�b``f``�������ˀ �����YL�B���xY��2�hй�]�T�p��� �s@����.;����f"3�K�Ɍ !&fM�y �Vf�L�*%�\-� endstream endobj 55 0 obj >/Metadata 3 0 R/Outlines 7 0

All Wales Medicines Strategy Group2016

133. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials 27598833 2016 09 29 2016 12 23 1463-1326 19 1 2017 Jan Diabetes, obesity & metabolism Diabetes Obes Metab Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. 142-147 10.1111/dom.12785 Given inconsistent trial results (...) of sodium-glucose cotransporter 2 (SGLT2) inhibitors in addition to insulin therapy for treating type 2 diabetes mellitus (T2DM), a meta-analysis was performed to evaluate the efficacy and safety of this combination for T2DM by searching available randomized trials from PubMed, Embase, CENTRAL and ClinicalTrials.gov. Our meta-analysis included seven eligible placebo-controlled trials involving 4235 patients. Compared with placebo, SGLT2 inhibitor treatment was significantly associated with a mean

EvidenceUpdates2016

134. Effectiveness of HypoAware, a Brief Partly Web-Based Psychoeducational Intervention for Adults With Type 1 and Insulin-Treated Type 2 Diabetes and Problematic Hypoglycemia: A Cluster Randomized Controlled Trial

Effectiveness of HypoAware, a Brief Partly Web-Based Psychoeducational Intervention for Adults With Type 1 and Insulin-Treated Type 2 Diabetes and Problematic Hypoglycemia: A Cluster Randomized Controlled Trial 27797931 2016 10 31 2016 11 23 1935-5548 39 12 2016 Dec Diabetes care Diabetes Care Effectiveness of HypoAware, a Brief Partly Web-Based Psychoeducational Intervention for Adults With Type 1 and Insulin-Treated Type 2 Diabetes and Problematic Hypoglycemia: A Cluster Randomized Controlled (...) Trial. 2190-2196 To establish the effectiveness of a brief, partly web-based group intervention, HypoAware, in patients with problematic hypoglycemia, in terms of the reduction of severe hypoglycemic episodes, impaired hypoglycemia awareness, and worries. A two-arm, cluster randomized controlled trial was conducted in insulin-treated patients with problematic hypoglycemia in eight Dutch clinics comparing HypoAware with care as usual. Primary outcomes included self-reported severe hypoglycemia

EvidenceUpdates2016

135. The effects of vitamin D supplementation on adiponectin level and insulin resistance in first-degree relatives of subjects with type 2 diabetes: a randomized double-blinded controlled trial.

The effects of vitamin D supplementation on adiponectin level and insulin resistance in first-degree relatives of subjects with type 2 diabetes: a randomized double-blinded controlled trial. 27790335 2016 10 28 2017 02 24 8 9 2016 Sep Electronic physician Electron Physician The effects of vitamin D supplementation on adiponectin level and insulin resistance in first-degree relatives of subjects with type 2 diabetes: a randomized double-blinded controlled trial. 2849-2854 Despite the certain (...) role of both vitamin D and adiponectin in the regulation of insulin sensitivity, the interaction between these two agents has remained uncertain. The present study aimed to determine whether vitamin D is able to change plasma adiponectin and affect glucose homeostasis and insulin sensitivity in first-degree relatives of subjects with type 2 diabetes. This randomized clinical trial was conducted at Clinic of Shahid Sadoughi Hospital in Yazd, Iran, from January 25, 2012 to December 25, 2014

Electronic physician2016 Full Text: Link to full Text with Trip Pro

136. Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortium

Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortium 27942580 2018 11 13 2374-4677 2 2016 NPJ breast cancer NPJ Breast Cancer Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortium. 16034 The insulin/insulin-like growth factor (IGF) system and related (...) pathways such as growth hormone, and leptin signaling have a key role in cancer development. It is unclear how germline variation in these pathways affects breast cancer risk. We conducted gene-based analyses of 184 genes in the insulin/IGF, growth hormone, and leptin pathways to identify genetic variation associated with risk of breast cancer overall, and for estrogen receptor (ER) subtypes. Tag single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina

NPJ breast cancer2016 Full Text: Link to full Text with Trip Pro

137. Challenges constraining access to insulin in the private-sector market of Delhi, India

Challenges constraining access to insulin in the private-sector market of Delhi, India 28588966 2018 11 13 2059-7908 1 3 2016 BMJ global health BMJ Glob Health Challenges constraining access to insulin in the private-sector market of Delhi, India. e000112 10.1136/bmjgh-2016-000112 India's majority of patients-including those living with diabetes-seek healthcare in the private sector through out-of-pocket (OOP) payments. We studied access to insulin in the private-sector market of Delhi state (...) , India. A modified World Health Organization/Health Action International (WHO/HAI) standard survey to assess insulin availability and prices, and qualitative interviews with insulin retailers (pharmacists) and wholesalers to understand insulin market dynamics. In 40 pharmacy outlets analysed, mean availability of the human and analogue insulins on the 2013 Delhi essential medicine list was 44.4% and 13.1%, respectively. 82% of pharmacies had domestically manufactured human insulin phials, primarily

BMJ global health2016 Full Text: Link to full Text with Trip Pro

138. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen

GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen 27340935 2016 08 19 2016 08 19 1875-9114 36 8 2016 Aug Pharmacotherapy Pharmacotherapy GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen. 893-905 10.1002/phar.1792 Adding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to basal insulin regimens has become a guideline-recommended treatment option for uncontrolled type 2 (...) diabetes. However, limited data exist to support the use of GLP-1 RAs with insulin regimens, including bolus insulin in patients with type 2 diabetes. The primary objectives of this review were to identify if the combination of a GLP-1 RA and an insulin regimen containing bolus insulin resulted in improvements in HbA1c , weight loss, reduction in insulin doses, and to evaluate the side effect profile of this combination in terms of nausea and hypoglycemia risk. Eight studies using exenatide twice/day

EvidenceUpdates2016

139. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study 27436788 2016 09 15 2016 11 21 1463-1326 18 12 2016 Dec Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study (...) . 1207-1216 10.1111/dom.12745 To examine the efficacy and safety of add-on ipragliflozin in Japanese patients with type 2 diabetes in the early stage of insulin therapy. Patients treated with insulin (bolus component <30% of total daily dose) with/without a dipeptidyl peptidase-4 (DPP-4) inhibitor were randomized to receive placebo (n = 87) or ipragliflozin (n = 175) for 16 weeks. The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline. Secondary endpoints included changes

EvidenceUpdates2016

140. The relation of anthropometric measurements and insulin resistance in patients with polycystic kidney disease

The relation of anthropometric measurements and insulin resistance in patients with polycystic kidney disease 28191534 2018 11 13 2450-131X 4 3 2016 Sep 01 Journal of translational internal medicine J Transl Int Med The relation of anthropometric measurements and insulin resistance in patients with polycystic kidney disease. 127-134 10.1515/jtim-2016-0029 To examine the frequency of insulin resistance (IR) and its relation with anthropometric measurements in patients with autosomal dominant (...) polycystic kidney disease (ADPKD). Nonobese 82 patients with ADPKD and 58 age matched healthy controls were enrolled into the study. None of participants were diabetic or receiving renal replacement therapies (RRT). IR was determined by homeostasis model assessment of insulin resistance (HOMA-IR) formula. Tanita body composition analyzer was used for anthropometric measurements. Creatinine clearance of participant were assessed by the modification of diet in renal diseases (MDRD). Patients with ADPKD had

Journal of translational internal medicine2016 Full Text: Link to full Text with Trip Pro